https://www.theedgemarkets.com/article/when-glove-party-ends-not-just-shareholders-get-burnt?type=corporate

Shud hv some news

Listed on 18th

Heavy volumn might b due to this
Details of Corporate Proposal
Involve issuance of new type/class of securities ? No
Types of corporate proposal Others
Details of corporate proposal Conversion of Redeemable Convertible Notes
No. of shares issued under this corporate proposal 98,765,432
Issue price per share ($$) Malaysian Ringgit (MYR) 0.0810
Par Value($$) (if applicable) Malaysian Ringgit (MYR) 0.000

When they think the time is right and they are in the mood to play wt us...they will come out and play...at the current moment they are nowhere to b seen...

WB fr 71cts dived down straight to 61cts...scary

KUALA LUMPUR: XOX Bhd has signed an agreement with Nexion to explore a deployment of next generation cyber security systems in Malaysia.


Nexion, listed on the Hong Kong Stock Exchange's Gem Board, is a cyber security software company, handling various aspects of cyber security including anti malware, anti-phishing and data protection.


In a statement today, XOX said both parties planned to jointly provide Software as a Service (SaaS) models to individuals, small and medium enterprises (SMEs) and enterprises in Malaysia.

XOX, Mastercard in e-wallet talk?
The partnership will see technical exchanges between the parties on cyber security, data preservation and retention, cyber intelligence and machine learning, all of which can be applied directly into XOX's embedded sim technology.

As part of the digital transformation wave that is hitting the marketplace, alongside XOX's recent partnership with microfinancing and Alipay, XOX with a subscriber base of 2.2 million would be facing a variety of challenges in terms of cyber security, it said.

XOX said the pact would strengthen its capability to provide fast, secure and robust services to all its subscribers and provide a platform to adopt enterprise level businesses.

"All businesses and organisations need to digitally transform, in order to keep pace with the current environment.

"With 5G on the horizon, encouraging massive data transfers at high speed, the need for cyber security and reliability of networks becomes paramount," said XOX executive director Roy Ho.

This time got news but no goreng goreng

30cts collecting

https://www.theedgemarkets.com/article/six-questions-top-gloves-boss-he-announces-over-rm1b-quarterly-net-profit-today?type=malaysia

Covid-19: Celebrating Malaysia Day in new norm
17 hours ago
Six questions for Top Glove’s boss as he announces over RM1b quarterly net profit today

By Syahirah Syed Jaafar & Kathy Fong | theedgemarkets.com | 2020-09-17 10:39:07
KUALA LUMPUR (Sept 17): Top Glove Corp Bhd will hog the limelight today as the world’s largest rubber glove maker will release its quarterly and annual earnings.

The market is expecting Top Glove to announce a quarterly net profit of no less than RM1 billion for the fourth financial quarter ended Aug 31, 2020 (4QFY20). It will be the largest ever quarterly net profit supported by the increase in average selling price (ASP) of disposable rubber gloves coupled with strong demand growth due to the Covid-19 pandemic globally.

The group’s executive chairman Tan Sri Lim Wee Chai last Friday already hinted that Top Glove will deliver stellar financial results for the financial year ended Aug 31, 2020 (FY20) and FY21.

"Our prospects and the glove industry remain promising. Global demand for gloves is growing steadily at 10% to 12% per annum driven by strong market fundamentals,” Lim said in a note posted on the company’s official website last week. The comment was seen as a message to stem the recent sharp fall in Top Glove’s share price.

The group’s shares rebounded to RM8.43 on Tuesday, up 30% from the low of RM6.45 last Thursday.

Besides the stellar set of earnings that investors are looking forward to, there are still issues awaiting Lim to address while Top Glove’s share price climbs further.

1. Vaccine, a curb on glove demand?
The surge in disposal glove usage worldwide is mainly driven by the pandemic. Does Lim expect the current high demand for rubber gloves to be affected by the availability of vaccines, which will be more effective to contain the spread of the virus?

The race to develop a Covid-19 vaccine is ongoing globally. The latest news is that coronavirus vaccines being developed in China may be ready for use by the general public as early as November, according to Chinese Center for Disease Control and Prevention (CDC).

China has four Covid-19 vaccines in the final stage of clinical trials. At least three of those have already been offered to essential workers under an emergency use programme launched in July.

2. Stockpile on gloves
Is the existing strong orders the result of stockpiling by distributors amid concerns on supply shortage?

If the demand is partly driven by stockpiling, this might mean that the glove makers are producing for future consumption far ahead.

On the other hand, operating theatres in hospitals are not occupied most of the time since the pandemic. It is a global trend that people are postponing elective procedures that are not life threatening. Many private hospitals are suffering from low activities.

Lim may want to enlighten the investing community on the details of the demand pattern moving forward. In short, how sustainable is the current strong demand that has driven Top Glove’s earnings to above RM1 billion? How would the demand pattern be like in the coming 18 months?

3. New entrants, a cause of oversupply
Over the past four months, there has been a rush to enter the rubber glove industry.

These new players, for instance Inix Technologies Holdings Bhd and AT Systematization Bhd, are setting up plants planning to start production next year to help fulfil the anticipated strong demand.

Rome wasn’t built in a day. Could rubber glove plants be built in months enabling the new entrants to tap onto the current strong demand?

Do the new facilities built to produce rubber gloves cause any concerns to the incumbents, who are also expanding their capacity aggressively?

4. Will US Customs detention order be revoked by year-end?
It has been two months since the US Customs has imposed a detention order on rubber gloves produced by the group’s two subsidiaries, namely Top Glove Sdn Bhd and TG Medical Sdn Bhd, on July 15.

On Sept 7, Top Glove said it has

In coronavirus vaccine race, China inoculates thousands before trials are completed



By David Stanway, Miyoung Kim | Reuters | 2020-09-16 12:53:02

SHANGHAI/SINGAPORE (Sep 16): China is inoculating tens of thousands of its citizens with experimental coronavirus vaccines and attracting international interest in their development, despite expert concerns over the safety of drugs that have not completed standard testing.
China launched a vaccine emergency use programme in July, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and U.S.-listed Sinovac Biotech. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Aiming to protect essential workers and reduce the likelihood of a resurgence, the vaccines are also grabbing attention in the global scramble by governments to secure supplies, potentially helping reframe China’s perceived role in the pandemic.
Beijing has not released official data on the uptake in domestic targeted groups, which include medical, transport and food market workers.
But China National Biotec Group (CNBG), the Sinopharm unit developing two of the emergency use vaccines, and Sinovac have confirmed that at least tens of thousands of people have been inoculated. Additionally, CNBG said it had given hundreds of thousands of doses; one of its vaccines requires an individual receive two or three shots to be inoculated.
Beijing has engaged a public, top-down approach to endorse the experimental vaccines and foster community support. Among those lining up for shots early on were the chief executives of Sinovac and Sinopharm and the military’s research chief.
The chief biosafety expert at the Chinese Center for Disease Control and Prevention (CDC) revealed this week that she too had been injected in April as she announced the potential that at least some of the vaccines would be ready for public use as early as November.
“So far, among the people who who were vaccinated, no one has been sick with the disease,” Guizhen Wu said on state TV. “So far, (the vaccination scheme) works very well. No side effect occurred.”
Wu’s comments were broadly in line with comments by CNBG last week that none of tens of thousands of people who travelled to high-risk countries and regions after being vaccinated had been infected, and there was “no case of obvious adverse reaction”.

SAFETY CONCERNS

China’s approach runs counter to that of many Western countries, where experts have warned against authorizing the emergency use of vaccines that have not completed testing, citing a lack of understanding about longer-term efficacy and potential side effects.
Anna Durbin, a vaccine researcher at Johns Hopkins University, described China’s emergency use programme as “very problematic,” saying it was impossible to judge efficacy without a clinical trial standard control group.
“You’re vaccinating people and you don’t know if it’s going to protect them,” Durbin told Reuters, adding recipients of the experimental vaccines could eschew other protective measures.
Vaccine safety came into sharp focus last week when AstraZeneca Plc paused late-stage clinical trials of its COVID-19 vaccine, one of the most advanced in development.
The company resumed British trials over the weekend after receiving the green light from safety watchdogs, and, along with other leading Western vaccine makers has pledged to uphold scientific study standards and reject any political pressure to rush the process.
Russia is one of the few other countries to authorise the use of an experimental vaccine, making its own “Sputnik V” vaccine mandatory for certain groups including teachers. India is considering emergency authorization for a vaccine, particularly for the elderly and people in high-risk workplaces.

FOREIGN BUYERS

The UAE authorized the emergency use of a Sinopharm vaccine this week, the first international emergency clearance for one of China’s vaccines, just six weeks after human trials began in the Gulf Arab state. UAE officials reported mild and expected side effects, but no severe side effects, during those trials.
CanSino has been approached by several countries, a source familiar with the discussions told Reuters, adding the military’s approval helped attract foreign interest. The person declined to name the countries engaged in talks.
CanSino, which has trials planned in Pakistan and Russia for the vaccine developed with China’s military research unit, did not respond to a request for comment.
Zhang Yuntao, CNBG vice president told Reuters his company has received interest from foreign countries to buy about 500 million doses of its experimental vaccine.
“China clearly wants to reorient that narrative in a way that it is viewed as a solution rather than a cause of the pandemic,” Yanzhong Huang, Senior Fellow for Global Health, Council on Foreign Relations, a U.S.-based think tank.
“That narr

Good news alrdy come

2 days lah limit up

KUALA LUMPUR: Anzo Holdings Bhd may have bagged a new contract worth RM1.3 billion to RM1.5 billion to export copper scrap to Japan and South Korea.
Sources said the company might announce the potential deal as early as next week.
It is believed that Anzo will start exporting the copper scrap to Japan and South Korea effective next month via a company with an AP (approved permit) licence.
The contract will create new business opportunities for Anzo in the export markets, said sources with knowledge on the matter.

YOU MAY ALSO LIKE

Anzo bags RM1.3bil order to supply copper scrap

Vivocom to win RM600m deal?

Emergency summit to seal Brexit deal?

AppAsia to bag RM2bil deal with TM?

The stock traded heavily yesterday, rising as much as 5.5 sen just after midday, before closing the day at 14 sen.
Some 232.4 million shares changed hands.
Anzo was one of the most active stocks traded on Bursa Malaysia.
The potential copper contract will be the second major win for Anzo this year.
In June, Anzo won a RM1.3 billion contract to supply copper scrap indirectly to a steel-making group in South Korea effective from July 1.
Anzo, which is being looked at by global funds from Hong Kong and China, had entered into a supply agreement with CSTME Resources Sdn Bhd, one of the major importers and exporters of non-ferrous materials in Malaysia.
In a recent filing with Bursa, Anzo had said that it would supply up to 60,000 tonnes of copper scrap to CSTME at RM23,000 per tonne over 40 months.
It is unclear if Anzo will also work with CSTME, which has an AP licence, for the new job.
Anzo, which is involved in property development and timber products, had in the last two years been actively seeking new business to diversify its income stream after posting losses for many quarters because of market conditions.
Its managing director Datuk Eddie Chai Woon Chet told the New Straits Times previously that Anzo was expected to turn around in the current year ending July 31, 2020.
This could be possible given that Anzo has already supplied close to 4,500 tonnes of copper to South Korea, worth about RM90 million since July 1.

Limit up 2molo

KUALA LUMPUR: Hartalega Holdings Bhd says demand for rubber gloves won’t be affected by vaccines for the Covid-19 coronavirus and will continue to outstrip supply in the next three to four years.

The pandemic has changed users’ behavior, that has resulted in the demand for gloves, chairman Kuan Kam Hon told reporters. Demand for usage in developed countries have increased 30% while in developing countries, usage has more than doubled, he says.


The industry cannot meet the 120b of additional demand for gloves. This demand can only be fulfilled in three years, he adds.

Spot prices for gloves have jumped 30% this quarter and he expects them to increase 40-50% in coming quarters, he says.

Glove prices are now three times higher compared to those during pre-covid-19.

Hartalega earmarked RM1.5bil investment to build four plants, of which first two lines will be operational by October 2021.

Another RM3bil is for its next expansion phase, its so-called NGC2, which will be fully completed in seven years. - Bloomberg

KUALA LUMPUR: Hartalega Holdings Bhd says demand for rubber gloves won’t be affected by vaccines for the Covid-19 coronavirus and will continue to outstrip supply in the next three to four years.

The pandemic has changed users’ behavior, that has resulted in the demand for gloves, chairman Kuan Kam Hon told reporters. Demand for usage in developed countries have increased 30% while in developing countries, usage has more than doubled, he says.


The industry cannot meet the 120b of additional demand for gloves. This demand can only be fulfilled in three years, he adds.

Spot prices for gloves have jumped 30% this quarter and he expects them to increase 40-50% in coming quarters, he says.

Glove prices are now three times higher compared to those during pre-covid-19.

Hartalega earmarked RM1.5bil investment to build four plants, of which first two lines will be operational by October 2021.

Another RM3bil is for its next expansion phase, its so-called NGC2, which will be fully completed in seven years. - Bloomberg

At least after co reply we wil know whether is time
to run or stay on for the ride...If true there is an annoucement we extend our stay n ride on wt the tide ...if the co report no major news or development then ...Cabut

Heavy volumn n price gapped up for 2 days ...sooner or later need to annouce as This Counter shud alrdy fall under SC radar like most penny stocks...the most 2 days play then slapped wt UMA query....then the co wil need to reply

Ths show aint over

Goin up

Is the ride over? Price vr stable at 18-19cts ..
news not yet out( if there is even 1) ....just ride wt it...if is pump n dump ...alrdy dump dump ...why stil hold it at 18-19cts....sthing definitely brewing...just got to wait and see...if not news vr obvious wil dump price wil dropped to 9cts..
so far no indication of dumping activities by market maker

It aint over til is over

Stil no announcement ...or no at all

Quick take: Parkson jumps 115% in active trade
https://www.thestar.com.my/business/business-news/2020/09/14/quick-take-parkson-jumps-115-in-active-trade

Look at the price stable at 18-19 up almost 100% if wanna dump alrdy dump

Yes i also is not end game as yet

Yes i believe too ...vr soon... hopefully anor round...market maker alrdy pushed up til 30cts along the way accumulated at higher price...dont think wil just gapped down...my 2cts

I dont think is over...wait n see any annoucement in the afternoon

As long as no news i think gap up again

Limit up coming

Bkn naik sebalik nya MELONJAT

Selagi tiada berita akan terus naik

Limit up ...our TP

Who knows limit up

Ride til news annoucement

Ride wt it...

Better dont announce yet let it run up farther

As long as no news coming out as yet share price wil fly up

https://www.theedgemarkets.com/article/latest-message-top-glove-chairman-asserts-extremely-robust-quarters-ahead-order-buildup?type=malaysia

39.5 cts done

Good co

AS the share prices of rubber glove companies continue to soar, many investors may not be aware that D’Nonce Technology Bhd, a Penang-based diversified engineering solutions provider, is also part of this growth story.

That is because D’Nonce produces packaging boxes for major glove makers in Thailand. Its factory is in Sadao, in Songkhla province, the country’s glove manufacturing hub.

D’Nonce group CEO Tho Yow Yin tells The Edge in an interview that the general public is not aware that the group is an indirect beneficiary of the Covid-19 pandemic, or rather, a direct beneficiary of higher glove demand.

https://www.theedgemarkets.com/article/dnonce-technology-ride-glove-growth-story?type=corporate

At least over rm1 price

this stock can keep for long term...wil slowly gap up

Is being awhile now Iris share price didnt dropped below 37cts....today broken n closed at 36.5cts...

Hopefully Iris wil fly high 2molo...

Only in Klse..
when listed co got good qr or new project its listed share price tends to go down...